Stock Analysts’ updated eps estimates for Monday, June 3rd:

Aduro BioTech (NASDAQ:ADRO) was downgraded by analysts at Oppenheimer Holdings Inc. from an outperform rating to a market perform rating.

Big Lots (NYSE:BIG) had its target price reduced by Telsey Advisory Group from $40.00 to $32.00. They currently have a market perform rating on the stock.

Big Lots (NYSE:BIG) was downgraded by analysts at Bank of America Corp from a buy rating to an underperform rating.

BT Group (NYSE:BT) was upgraded by analysts at Credit Suisse Group AG from a neutral rating to an outperform rating.

Cigna (NYSE:CI) had its price target cut by Citigroup Inc from $228.00 to $203.00. They currently have a buy rating on the stock.

Ciena (NYSE:CIEN) had its hold rating reissued by analysts at Rosenblatt Securities. The firm currently has a $38.00 target price on the stock. The analysts wrote, “We expect CIEN to report near in-line F2Q19 results and outlook when it reports Thursday morning June 6 th . We look for slowing hyperscale sales to be balanced by steady growth from US and European carriers. We expect CIEN to maintain its outlook of ~ +2% y/y revenue growth for F2H19 and do not expect management to raise expectations for 2020 despite early positive signs of potential international share gains from Chinese suppliers. We believe CIEN has zero exposure to China sales and likely minimal supply chain exposure. We make no changes to our FY19 outlook, wherein revenues are near inline with consensus but earnings are $.10 light of consensus, and introduce our FY20 estimates, in-line with consensus. We maintain our neutral rating and increase our price target from $36 to $38.””

Cree (NASDAQ:CREE) was downgraded by analysts at BMO Capital Markets from an outperform rating to a market perform rating. BMO Capital Markets currently has $55.00 price target on the stock.

CytomX Therapeutics (NASDAQ:CTMX) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. The firm currently has a $23.00 target price on the stock, up from their previous target price of $21.00.

Deciphera Pharmaceuticals (NASDAQ:DCPH) had its target price increased by Piper Jaffray Companies from $50.00 to $55.00. The firm currently has an overweight rating on the stock. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Dynavax Technologies (NASDAQ:DVAX) had its buy rating reissued by analysts at Cowen Inc.

Brinker International (NYSE:EAT) was upgraded by analysts at UBS Group AG from a sell rating to a neutral rating.

Emerald Expositions Events (NYSE:EEX) was downgraded by analysts at Goldman Sachs Group Inc from a buy rating to a neutral rating.

East West Bancorp (NASDAQ:EWBC) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $50.00 price target on the stock, down from their previous price target of $57.00.

Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by analysts at Wells Fargo & Co from an outperform rating to a market perform rating.

Fortive (NYSE:FTV) was downgraded by analysts at Cowen Inc from a market perform rating to an underperform rating. They currently have $65.00 target price on the stock, down from their previous target price of $75.00.

Global Blood Therapeutics (NASDAQ:GBT) had its buy rating reissued by analysts at Wedbush. The firm currently has a $107.00 target price on the stock.

HD Supply (NASDAQ:HDS) was upgraded by analysts at Longbow Research from a neutral rating to a buy rating.

IMV (NYSE:IMV) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $11.50 target price on the stock. The analysts wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success).””

Infinera (NASDAQ:INFN) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating.

Iovance Biotherapeutics (NASDAQ:IOVA) had its price target boosted by HC Wainwright from $26.00 to $32.00. HC Wainwright currently has a buy rating on the stock.

3M (NYSE:MMM) had its buy rating reaffirmed by analysts at Citigroup Inc. They currently have a $197.00 target price on the stock, down from their previous target price of $221.00.

Molina Healthcare (NYSE:MOH) was upgraded by analysts at BMO Capital Markets from a market perform rating to an outperform rating. BMO Capital Markets currently has $200.00 target price on the stock, up from their previous target price of $154.00.

Ocado Group (OTCMKTS:OCDGF) was downgraded by analysts at Jefferies Financial Group Inc from a hold rating to an underperform rating.

Royal Dutch Shell (NYSE:RDS.A) had its price target reduced by Cowen Inc from $80.00 to $75.00. They currently have an outperform rating on the stock.

Signet Jewelers (NYSE:SIG) had its target price lowered by Telsey Advisory Group from $28.00 to $22.00. Telsey Advisory Group currently has a market perform rating on the stock.

Skyworks Solutions (NASDAQ:SWKS) had its target price trimmed by Craig Hallum from $105.00 to $85.00. Craig Hallum currently has a buy rating on the stock.

Tate & Lyle (OTCMKTS:TATYY) was downgraded by analysts at Jefferies Financial Group Inc from a hold rating to an underperform rating.

WellCare Health Plans (NYSE:WCG) was downgraded by analysts at BMO Capital Markets from an outperform rating to a market perform rating.

Waste Management (NYSE:WM) was upgraded by analysts at Royal Bank of Canada from a sector perform rating to an outperform rating.

Waste Management (NYSE:WM) had its overweight rating reaffirmed by analysts at KeyCorp. The firm currently has a $120.00 target price on the stock, up from their previous target price of $112.00.

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.